We use cookies to improve your experience on our site. Please accept the Privacy Policy to continue.

EVUSHELD Treatment


The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to make EVUSHELD available during the COVID-19 pandemic.

EVUSHELD is an investigational medicine used in adults and adolescents 12 years of age and older who weigh at least 88 pounds for preexposure prophylaxis for prevention of COVID-19.

EVUSHELD is for persons who are:

  • not currently infected with SARS-CoV-2 and who have not had recent known close contact with someone who is infected with SARS-CoV-2 and
  • Who have moderate to severe immune compromise due to a medical condition or have received immunosuppressive medicines or treatments and may not mount an adequate immune response to COVID-19 vaccination or
  • For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (such as severe allergic reaction) to a COVID-19 vaccine(s) or COVID-19 vaccine ingredient(s).
  • NYC Health + Hospitals/Bellevue
  • NYC Health + Hospitals/Kings County
  • NYC Health + Hospitals/Queens

Community providers interested in referring their patients for EVUSHELD at NYC Health + Hospitals will need to either complete an eform or call 212 COVID-19.